Navigation Links
Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Date:6/19/2012

CRANBURY, N.J., June 19, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted. AZD2820 is a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies.

The Phase 1 clinical trial of AZD2820 was halted by the Safety Review Committee established by AstraZeneca after meeting a predefined stopping criterion. The stopping criterion was a serious adverse event. It is suspected that the subject may have had an allergic reaction following his first dose. The subject was treated at the clinical site and has fully recovered. A review and investigation of the incident has commenced.

"We are pleased that the subject has fully recovered from this unfortunate adverse event and we will work closely with our partner AstraZeneca to investigate the cause of this incident and the overall plans for the AZD2820 program," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "AstraZeneca has confirmed their remaining commitment to the continued advancement of melanocortin agonists for treatment of obesity, including a number of collaboration compounds in various stages of preclinical testing."

The phase I single center study, conducted by AstraZeneca, targeted enrolling 72 obese but otherwise healthy male subjects, with a body mass index between 30 and 35 kg/m2, in a randomized, single-blind, placebo-controlled, trial. Eleven subjects had completed their dosing regimen prior to the halting of the trial. The primary outcome of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD2820 after administration of multiple ascending doses. Another Phase 1 single ascending dose study of AZD2820 was finalize
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
2. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
3. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
4. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
8. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
9. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
10. OrthoAccel Technologies, Inc. Names U.S. National Sales Director
11. Metamaterials, quantum dots show promise for new technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 PrimeSource ... construction materials, selected SoundConnect to support ... cloud based audio and web conferencing platform GlobalMeet ... support PrimeSource’s employees’ needs. SoundConnect delivers award ... , PrimeSource Building Products will be utilizing ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Whitehouse Laboratories ... long term partnership with PTI Inspection Systems ... with state of the art leak testing method development ... art instruments currently available. As part of this agreement, ... High Voltage Leak Detection Instrument developed and manufactured ...
(Date:8/27/2014)... August 27, 2014 Green & Grow ... Series B funding and secured Otter Capital as a ... will accelerate commercialization of GGI’s Agriplier™ technology, building on ... , “Since our first meeting, we have been ... biological product space,” said Alan Sobba, President and CEO ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... Extension until February 3, 2009 to meet continued listing ... VSCP ) today announced that the Nasdaq Hearings ... the Nasdaq Capital Market and has,allowed the Company until ... price. The Panel,s decision represents the full extent of ...
... Inc., a,privately held biopharmaceutical company, announced today that ... executive vice president and chief,financial officer., "Bob ... 28 years of,financial management experience to Horizon, including ... private companies," said Timothy P.,Walbert, president and chief ...
... have used a wide variety of materials to build ... business, nanotechnology researchers can often be limited by the ... State University researcher Hao Yan has avoided these pitfalls ... nanostructures inside a living cell. , The results ...
Cached Biology Technology:Nasdaq Grants VirtualScopics' Request for Continued Listing 2Nasdaq Grants VirtualScopics' Request for Continued Listing 3Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer 2Using living cells as nanotechnology factories 2Using living cells as nanotechnology factories 3
(Date:8/27/2014)... is related to ability that we already possess. For ... more easily than learning how to hit a tennis ... Neural Basis of Cognition (CNBC)a joint program between the ... fundamental constraint in the brain that may explain why ... Aug. 28, 2014, issue of Nature , they ...
(Date:8/27/2014)... risk to Europe based upon a proxy for impact ... a ,big data, approach to scientific research. , The ... Health ranked the top 100 pathogens affecting humans and ... which, they believe, will help governments across the continent ... diseases, including as a result of climate change, and ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
Breaking Biology News(10 mins):Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... graduate student at the Icahn School of Medicine at Mount ... "30 Under 30" list in "Science and Health." The ... transforming for the better, opening up to revolutionary new ideas ... . Ms. Shapiro, 25, a native of Rochester, New ...
... study in this month,s edition of the Journal of ... for melanoma, the most dangerous form of skin cancer. MicroRNA ... and which stay silent. Melanoma tends to lack microRNA-26a, which ... negative," says Yiqun Shellman, PhD, investigator at the CU Cancer ...
... of androgen deprivation therapies to prevent precancerous prostate abnormalities ... in men with precancers with specific genetic alterations, according ... Cancer Discovery , a journal of the American ... survival of prostate cancer cells are very dependent on ...
Cached Biology News:Mount Sinai grad student, 25, named to Forbes '30 Under 30' in Science and Healthcare 2Serendipity points to new potential target and therapy for melanoma 2Preventing prostate cancer through androgen deprivation may have harmful effects 2
Improves spot morphology and DNA binding to the slide resulting in increased hybridization signal. ID Clarifier: Optimized spotting solution for use with SigmaScreen APS Coated Slides for Microarrays...
... strength adhesive system which facilitates the easy removal ... either side of the frame are of differing ... has an easy release adhesive whereas the reverse, ... bond. This means that when the coverslip is ...
... description: Humidity wells in the base hold ... humidity and probe hydration around the edges ... the risk of waterbath contamination. This chamber ... waterbaths or hybridisation ovens. Linkage: This CLS ...
... cDNA Synthesis and Labeling Kit generates labeled ... First unmodified cDNA is made via a ... an Oligo(dT) primer. Unlike other methods, there ... the reverse transcription reaction. This unmodified cDNA ...
Biology Products: